Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:NUVB 20 November 2025 - 12 January 2026

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio shares fell 4.7% to $8.05 Friday afternoon, underperforming biotech peers. UBS began coverage at Neutral with a $10 target, while RBC raised its target to $9 and reiterated Outperform. CEO David Hung is set to present at the J.P. Morgan Healthcare Conference on Jan. 13. Investors await early March results for updates on IBTROZI’s launch and pipeline spending.
9 January 2026
·
Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio shares surged 49% to $7.15 on November 20, 2025, hitting a three-year high after Q3 revenue of $13.1 million nearly doubled analyst estimates. Uptake of its lung-cancer drug IBTROZI drove $7.7 million in U.S. sales and 204 new patient starts. Multiple analysts raised price targets, with the average now at $10.13. Trading volume spiked, extending a multi-day rally.
20 November 2025
·

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop